The Dermatology Digest

SEPTEMBER 20, 2024

s Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT). Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s Dr. Robert B.

Office 74

Office Safety Clinic Medical 74

The Dermatology Digest

SEPTEMBER 12, 2024

In the confirmatory phase 3 study (LIBERTY-CUPID Study C), dupilumab met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines. At 24 weeks, efficacy among patients receiving Dupixent compared to placebo was as follows: 8.64-point

Safety 36

Safety Office Medical Dermatology 36

The Dermatology Digest

JULY 29, 2024

Key secondary endpoints will include PASI 90, PASI 100 and sPGA 0 measured at Weeks 16 and 24, and safety and tolerability. Patients completing Week 24 will have the opportunity to participate in a long-term extension (LTE) trial, ONWARD3, that will evaluate durability and maintenance of response and long-term safety.

Clinic 36

Clinic Safety Office Treatments 36

The Dermatology Digest

JANUARY 20, 2024

By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch. Evommune, Inc.

Safety 74

Safety Office Dermatitis Dermatology 74

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. There were no treatment-related Serious Adverse Events (SAEs). Zoryve foam was approved by the U.S.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

Natural Beauty Med Spa

APRIL 28, 2024

Laser skin resurfacing is a popular cosmetic treatment that has the potential to drastically improve the appearance of the skin. However, you might be reluctant to commit to it due to concerns about safety. Another factor that should be kept in mind is the professional that performs the treatment. Is it worth it?

Med Spa 52

Med Spa Scarring Safety Makeup 52

Lipgloss and Aftershave

NOVEMBER 1, 2024

Jenni Nagle, L+A CO-Founder had a CO2 laser treatment and kept an eight day diary of her recovery process! For estheticians and skincare professionals, addressing pigmentation involves understanding and applying a multimodality treatment approach, which combines various techniques to tackle pigmentation through multiple mechanisms.

Chemical Peels 52

Chemical Peels Hyperpigmentation Vitamin C Microneedling 52

The Dermatology Digest

APRIL 18, 2024

Extra-strength 40U formulation of prabotulinumtoxinA-xvfs (Jeuveau, Evolus) performed well in a Phase 2 trial for the treatment of moderate to severe glabellar lines in adults. The safety profile was similar across all three arms and overall, 88.9% The safety profile was similar across all three arms and overall, 88.9%

Safety 36

Safety Office Surgery Dermatology 36

The Dermatology Digest

FEBRUARY 14, 2024

VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. VTAMA cream, 1% data indicated no new safety or tolerability signals of concern in this population including children 2 years of age and older.

Dermatitis 74

Dermatitis Office Management Eczema 74

The Dermatology Digest

SEPTEMBER 30, 2024

s ESK-001 is a highly selective TYK2 inhibitor currently being evaluated in the Phase 3 ONWARD clinical program for the treatment of moderate-to-severe plaque psoriasis. Treatment emergent adverse event (TEAE) frequency and severity were similar across study arms, with the majority being mild-to-moderate and self-limited. Alumis Inc.’s

Safety 36

Safety Clinic Sustainability Office 36

The Dermatology Digest

MAY 16, 2024

Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, adds: “With only two FDA approved biologics, there is still an urgent need for new treatment options that treat all patient types and lesions, with the opportunity for inflammatory remission. HiSCR75 and beyond).

Safety 68

Safety Clinic Dermatology Office 68

The Dermatology Digest

FEBRUARY 22, 2024

for the treatment of seborrheic keratoses. “We for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D., The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

FEBRUARY 22, 2024

for the treatment of seborrheic keratoses. “We for the treatment of SK lesions, the most common benign tumors of the skin,” shares Karl Beutner, M.D., The primary endpoints of the study are the proportion of SK lesions with a Physician Lesion Assessment (PLA) score of clear (PLA=0) at last visit and the safety of SM-020 gel 1.0%

Safety 36

Safety Clinic Office Hyperpigmentation 36

Aesthetics Advisor

OCTOBER 7, 2023

Based on rapidly emerging clinical trials evidence, the FLCCC team has developed the I-MASK+ protocol for prophylaxis and at home treatment of early stage COVID-19 and has now divided the I-MASK protocol into I-CARE and I-PREVENT protocols. Treatment is therefore highly stage-specific. Treatment of BA.4/BA.5/BQ.1.1

Treatments 69

Treatments Therapy Medical Vitamin C 69

The Dermatology Digest

JANUARY 14, 2024

The PDE4 inhibitor is the first topical treatment for seborrheic dermatitis with a new mechanism of action in more than 20 years. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. There were no treatment-related Serious Adverse Events (SAEs). of the total study population).

Dermatitis 72

Dermatitis Dermatology Office Safety 72

The Dermatology Digest

NOVEMBER 6, 2024

This award was established this year to accelerate the translation of research into potential treatments and diagnostics for lupus. He will test ONT01, which has shown promising results in mouse models, in a phase 1b trial to assess its safety in people with lupus.

Hospital 36

Hospital Therapy Management Networking 36

The Dermatology Digest

AUGUST 21, 2024

The trial did not show a statistically significant difference between the proportion of patients treated with TMB-001 responding to treatment after 12 weeks compared with patients treated with vehicle. After encouraging phase 2b results, we observed an unexpectedly high vehicle response in this trial.

Pharmaceutical 36

Pharmaceutical Clinic Office Safety 36

The Dermatology Digest

JANUARY 5, 2024

s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. The last patient has been dosed in Part 2 of Verrica Pharmaceuticals Inc.’s VP-315 is a chemotherapeutic administered intratumorally.

Pharmaceutical 36

Pharmaceutical Safety Office Clinic 36

The Dermatology Digest

JANUARY 5, 2024

Food and Drug Administration (FDA) seeking approval for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The NDA submission is based on positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea.

Rosacea 36

Rosacea Medical Office Safety 36

The Dermatology Digest

APRIL 17, 2024

Patient enrollment is now complete in Celldex’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). Patients then enter a follow-up phase for an additional 24 weeks.

Safety 36

Safety Injections Therapy Office 36

The Dermatology Digest

JANUARY 24, 2024

Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules in people with severe chronic hand eczema, according to results from the DELTA FORCE Trial, which is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.

Eczema 36

Eczema Safety Office Treatments 36

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Dermatitis Therapy Dermatology 36

The Dermatology Digest

FEBRUARY 6, 2024

Food and Drug Administration (FDA) has issued a “no filing review issues identified” letter regarding Biofrontera’s sNDA (supplementary New Drug Application) which aims to increase the maximally approved dosage from one to three tubes of Ameluz per treatment.

Safety 28

Safety Office Therapy Ingredients 28

Southeastern Esthetics Institute

AUGUST 23, 2016

Estheticians must obtain written permission and treatment plans through the physician overseeing the practice, with monitoring by the physician of all notations within patient charts, products and modalities used, and any other thought process made throughout the duration of treatment.

Esthetician 195

Esthetician Esthetics Document Office 195

The Dermatology Digest

FEBRUARY 7, 2024

For the study, 255 participants were randomized into six treatment groups (placebo [n=43], 25 mg daily [n=43], 25 mg twice-daily [n=41], 50 mg daily [n=43], 100 mg daily [n=43], and 100 mg twice-daily [n=42]). Improvements were also consistent across Patient Reported Outcomes through Week 16.

Safety 36

Safety Clinic Office Dermatology 36

Fairlawn Aesthetic MD

JULY 19, 2023

It’s an innovative treatment in the field of aesthetic medicine that’s designed to help you look and feel your absolute best. The Cryo T-Shock procedure involves alternating cycles of cryo (cold) and thermo (heat) treatments applied directly to the skin. It’s a comfortable and safe treatment.

Treatments 36

Treatments Diet Consultation Consultations 36

The Dermatology Digest

JULY 22, 2024

“This opportunity to improve patient access through wider usage of a life-changing biological treatment emphasizes STADA’s purpose of Caring for People’s Health as a Trusted Partner.” “We We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech.

Partnerships 36

Partnerships Pharmaceutical Marketing Office 36

The Dermatology Digest

FEBRUARY 26, 2024

Sonelokimab is a novel investigational nanobody for the treatment of inflammatory disease. This represents a crucial step in offering a potential innovative treatment option to patients and their dedicated physicians, addressing a condition that is often under-recognized, under-treated and significantly impacts patients’ lives.”

Office 74

Office Safety Innovations Clinic 74

The Dermatology Digest

JANUARY 11, 2024

Vtama cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, steroid-free, topical cream for both acute treatment and long-term management of AD. Vtama cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S.

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

The Dermatology Digest

JANUARY 20, 2024

By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch. Evommune, Inc.

Safety 36

Safety Office Dermatitis Dermatology 36

The Dermatology Digest

AUGUST 14, 2024

s VP-315 is showing promise in the treatment of basal cell carcinoma, according to Part 2 of its Phase 2 clinical trial. The key preliminary Part 2 results were: No dose-limiting toxicities or Treatment-Related Serious Adverse Events were reported. Verrica Pharmaceuticals Inc.’s It’s very, very exciting data.”

Safety 36

Safety Pharmaceutical Clinic Dermatology 36

Art of Dermatology

MAY 17, 2024

At Art of Dermatology at the Laser and Skin Surgery Center of New York, patient safety and satisfaction is Dr. Jessica Krant’s primary concern. Making sure you are seeing a board-certified core cosmetic specialty physician (dermatologist, plastic surgeon, oculoplastic surgeon, or ENT facial plastic surgeon) in a real medical office is key.

Office 36

Office Surgery Safety Injections 36

The Dermatology Digest

FEBRUARY 27, 2024

“The approval of SIMLANDI marks the first high-concentration, citrate-free biosimilar to Humira with IC status,” says Dr. Eric Hughes, Executive Vice President Global R&D and Chief Medical Officer at Teva, in a news release.

Safety 36

Safety Marketing Pharmaceutical Partnerships 36

New Age Spa Institute

APRIL 18, 2024

” Laser treatments for hair removal and skin rejuvenation are an often-connected part of the aesthetics industry, and there are some critical points to consider before pursuing a career in this field. This distinction is crucial for both practitioners and clients to understand, ensuring treatments are conducted safely and legally.

Legal 52

Legal Hair Removal Safety Esthetician 52

The Dermatology Digest

JULY 23, 2024

Food and Drug Administration (FDA) approved XEOMIN (incobotulinumtoxinA) for the simultaneous treatment of forehead lines, frown lines, and crow’s feet. The total recommended XEOMIN dose for treatment is 20 units for glabellar frown lines, 20 units for horizontal forehead lines and 24 units for the crow’s feet for a total of 64 units.

Facials 36

Facials Partnerships Ingredients Injections 36

The Dermatology Digest

APRIL 22, 2024

Treatment was well-tolerated and no new safety signals were identified. Most patients on eblasakimab achieved EASI-90 and vIGA of 0 or 1 after just 16 weeks of treatment, with numbers unprecedented in other biologics AD studies. There were no reports of conjunctivitis or injection site reactions in the active or placebo arm.

Pharmaceutical 36

Pharmaceutical Dermatitis Eczema Injections 36

The Dermatology Digest

AUGUST 15, 2024

DermBiont’s SM-020 is performing well in an ongoing open label, multi-center Phase 2a study for the treatment of basal cell carcinoma (BCC), the Company reports. The safety of the drug product is being evaluated based on frequency of adverse events (AEs) and application site reactions (ASRs). and CEO of DermBiont, in a news release.

Clinic 36

Clinic Scarring Office Safety 36